US and Canada Report

Nontuberculous Mycobacteria Infections Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Abbott, Spero Therapeutics, Novartis AG, Janssen, RevImmune

Nontuberculous Mycobacteria Infections Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Abbott, Spero Therapeutics, Novartis AG, Janssen, RevImmune

August 30
10:01 2023
Nontuberculous Mycobacteria Infections Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Abbott, Spero Therapeutics, Novartis AG, Janssen, RevImmune
“Nontuberculous Mycobacteria Infections Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Nontuberculous Mycobacteria Infections, historical and forecasted epidemiology as well as the Nontuberculous Mycobacteria Infections market trends in the 7MM.

DelveInsight’s “Nontuberculous Mycobacteria Infections Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Nontuberculous Mycobacteria Infections, historical and forecasted epidemiology as well as the Nontuberculous Mycobacteria Infections market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Nontuberculous Mycobacteria Infections market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Nontuberculous Mycobacteria Infections Market Forecast

 

Some of the key facts of the Nontuberculous Mycobacteria Infections Market Report: 

  • The Nontuberculous Mycobacteria Infections market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • According to this systematic review and meta-analysis, the prevalence of NTM infections in individuals with non-CF bronchiectasis increased over the past 15 years, with an estimated 10% (9.75%, 95% CI 5.41% to 14.09%) global prevalence from 2006 to 2021 
  • Key Nontuberculous Mycobacteria Infections Companies: RedHill Biopharma, RevImmune, Paratek Pharmaceuticals, Insmed Incorporated, Savara Inc., Insmed Incorporated, Pfizer, Abbott, Spero Therapeutics, Novartis AG, Janssen, RevImmune, Nobelpharma Co Ltd, and others 
  • Key Nontuberculous Mycobacteria Infections Therapies: RHB-204, CYT107, Nuzyra, ALIS, Recombinant human interleukin-7, Inhaled molgramostim, LAI (Liposomal Amikacin for Inhalation), Rifabutin, Omadacycline, Clarithromycin, SPR720, and others
  • In compared to mild and severe cases, moderate NTMinfections cases have been found to be more prevalent
  • With 83,000 cases in 2021, there were a sizable number of frequent cases of Nontuberculous Mycobacteria infections reported in Japan
  • The Nontuberculous Mycobacteria epidemiology based on gender analyzed that moderate cases of Nontuberculous Mycobacteria infections are more prominent in comparison to mild and severe cases
  • The Nontuberculous Mycobacteria Infections market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Nontuberculous Mycobacteria Infections pipeline products will significantly revolutionize the Nontuberculous Mycobacteria Infections market dynamics.

 

Get a Free sample for the Nontuberculous Mycobacteria Infections Market Report 

https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-ntm-infections-market

 

Nontuberculous Mycobacteria Infections Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Nontuberculous Mycobacteria Infections Epidemiology Segmentation:

The Nontuberculous Mycobacteria Infections market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Nontuberculous Mycobacteria Infections
  • Prevalent Cases of Nontuberculous Mycobacteria Infections by severity
  • Gender-specific Prevalence of Nontuberculous Mycobacteria Infections
  • Diagnosed Cases of Episodic and Chronic Nontuberculous Mycobacteria Infections

 

Download the report to understand which factors are driving Nontuberculous Mycobacteria Infections epidemiology trends @ Nontuberculous Mycobacteria Infections Epidemiology Forecast

 

Nontuberculous Mycobacteria Infections Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Nontuberculous Mycobacteria Infections market or expected to get launched during the study period. The analysis covers Nontuberculous Mycobacteria Infections market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Nontuberculous Mycobacteria Infections Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Nontuberculous Mycobacteria Infections Therapies and Key Companies

  • RHB-204: RedHill Biopharma
  • CYT107: RevImmune
  • Nuzyra: Paratek Pharmaceuticals
  • ALIS: Insmed Incorporated
  • Recombinant human interleukin-7: Revimmune
  • Inhaled molgramostim: Savara Inc.
  • LAI (Liposomal Amikacin for Inhalation): Insmed Incorporated
  • Rifabutin: Pfizer
  • Omadacycline: Paratek Pharma
  • Clarithromycin: Abbott
  • SPR720: Spero Therapeutics

 

Discover more about therapies set to grab major Nontuberculous Mycobacteria Infections market share @ Nontuberculous Mycobacteria Infections Treatment Market

 

Scope of the Nontuberculous Mycobacteria Infections Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Nontuberculous Mycobacteria Infections Companies: RedHill Biopharma, RevImmune, Paratek Pharmaceuticals, Insmed Incorporated, Savara Inc., Insmed Incorporated, Pfizer, Abbott, Spero Therapeutics, Novartis AG, Janssen, RevImmune, Nobelpharma Co Ltd, and others
  • Key Nontuberculous Mycobacteria Infections Therapies: RHB-204, CYT107, Nuzyra, ALIS, Recombinant human interleukin-7, Inhaled molgramostim, LAI (Liposomal Amikacin for Inhalation), Rifabutin, Omadacycline, Clarithromycin, SPR720, and others
  • Nontuberculous Mycobacteria Infections Therapeutic Assessment: Nontuberculous Mycobacteria Infections current marketed and Nontuberculous Mycobacteria Infections emerging therapies
  • Nontuberculous Mycobacteria Infections Market Dynamics: Nontuberculous Mycobacteria Infections market drivers and Nontuberculous Mycobacteria Infections market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Nontuberculous Mycobacteria Infections Unmet Needs, KOL’s views, Analyst’s views, Nontuberculous Mycobacteria Infections Market Access and Reimbursement 

 

To know more about Nontuberculous Mycobacteria Infections companies working in the treatment market, visit @ Nontuberculous Mycobacteria Infections Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Nontuberculous Mycobacteria Infections Market Report Introduction

2. Executive Summary for Nontuberculous Mycobacteria Infections

3. SWOT analysis of Nontuberculous Mycobacteria Infections

4. Nontuberculous Mycobacteria Infections Patient Share (%) Overview at a Glance

5. Nontuberculous Mycobacteria Infections Market Overview at a Glance

6. Nontuberculous Mycobacteria Infections Disease Background and Overview

7. Nontuberculous Mycobacteria Infections Epidemiology and Patient Population

8. Country-Specific Patient Population of Nontuberculous Mycobacteria Infections 

9. Nontuberculous Mycobacteria Infections Current Treatment and Medical Practices

10. Nontuberculous Mycobacteria Infections Unmet Needs

11. Nontuberculous Mycobacteria Infections Emerging Therapies

12. Nontuberculous Mycobacteria Infections Market Outlook

13. Country-Wise Nontuberculous Mycobacteria Infections Market Analysis (2019–2032)

14. Nontuberculous Mycobacteria Infections Market Access and Reimbursement of Therapies

15. Nontuberculous Mycobacteria Infections Market Drivers

16. Nontuberculous Mycobacteria Infections Market Barriers

17.  Nontuberculous Mycobacteria Infections Appendix

18. Nontuberculous Mycobacteria Infections Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

About Author

admin

admin

Related Articles